Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial

BACKGROUND: Advanced biliary tract cancer has a poor prognosis. Cisplatin and gemcitabine is the standard first-line chemotherapy regimen, but no robust evidence is available for second-line chemotherapy. The aim of this study was to determine the benefit derived from second-line FOLFOX (folinic aci...

Descripción completa

Detalles Bibliográficos
Autores principales: Lamarca, Angela, Palmer, Daniel H, Wasan, Harpreet Singh, Ross, Paul J, Ma, Yuk Ting, Arora, Arvind, Falk, Stephen, Gillmore, Roopinder, Wadsley, Jonathan, Patel, Kinnari, Anthoney, Alan, Maraveyas, Anthony, Iveson, Tim, Waters, Justin S, Hobbs, Claire, Barber, Safia, Ryder, W David, Ramage, John, Davies, Linda M, Bridgewater, John A, Valle, Juan W
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lancet Pub. Group 2021
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8082275/
https://www.ncbi.nlm.nih.gov/pubmed/33798493
http://dx.doi.org/10.1016/S1470-2045(21)00027-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8082275/
https://www.ncbi.nlm.nih.gov/pubmed/33798493
http://dx.doi.org/10.1016/S1470-2045(21)00027-9

Ejemplares similares